Treatment of symptoms (incontinence, frequency, urgency) due to overactive bladder

Anticholinergic Agent

Distribution: Mean 279 L
Protein binding: Propiverine 90% to 95%; propiverine-N-oxide (main metabolite) 60%
Metabolism: Extensive via hepatic and intestinal enzymes, primarily by CYP3A4 and flavin-monooxygenases (FMO) 1 and 3
Bioavailability: Large first-pass effect
Half-life elimination: 14 to 16 hours
Time to peak, serum: ~10 hours
Excretion: Urine (60%, <1% unchanged); Feces (21%)

1. Hypersensitivity to propiverine or any component of the formulation
2. Gastrointestinal obstructive disorder; Intestinal atony; Toxic megacolon; severe ulcerative colitis
3. Angle-closure glaucoma; Myasthenia gravis; Tachyarrhythmias; Moderate or severe hepatic impairment; Significant degree of bladder outflow obstruction; Rare hereditary problems of galactose intolerance, glucose-galactose malabsorption, or congenital lactase deficiency; Children with rare hereditary problems of fructose intolerance or sucrose-isomaltase insufficiency

Use is not recommended in pregnancy.

Breastfeeding is not recommended by the manufacturer.

Fatigue, Hypotension, Dizziness, Fatigue, Headache, Pruritus, Skin rash, Polydipsia, Abdominal pain, Constipation, Dyspepsia, Diarrhea, Nausea, Vomiting, Dysuria, Increased post-void residual urine, Leukopenia, Increased serum transaminases, Oculomotor disturbance

30 mg once daily; may increase to a maximum of 45 mg once daily

0.8 mg/kg/day in 2 divided doses

Mild to moderate impairment: No dosage adjustment necessary
Severe impairment: Maximum 30 mg/day

Mild impairment: No dosage adjustments necessary
Moderate to severe impairment: Use is contraindicated